Combo of sacituzumab govitecan and enfortumab vedotin shows potential in urothelial carcinoma
October 31st 2023Combining the antibody-drug conjugates sacituzumab govitecan and enfortumab vedotin was safe, feasible, and produced high and early response rates in patients with treatment-resistant metastatic urothelial cancer.